NEWS
Europe’s Healthtech Scaleups Keep Proving Themselves Abroad First
Seven EIC club healthtech firms have CE marks and fresh capital, yet the first heart implant, FDA papers and a 327-subject trial keep landing outside Europe.
A French heart pump had its first human implant in Sydney on May 28, 2025. The patient, a 67-year-old grandfather from inland New South Wales, later received a donor heart after 84 days on the device. In the same European cohort, a Lithuanian echo tool now holds two U.S. FDA clearances, and a Barcelona stroke firm closed $56 million (about €49 million) on September 23, 2026 to finish an American trial.
Seven healthtech scaleups are being held up as answers to late diagnoses, crowded wards and diseases with thin treatment lists. They belong to the European Innovation Council Scaling Club. Europe still writes the grants. The first implant, the FDA letters and the trial cheques keep landing elsewhere.
A French Pump Meets an Australian Chest
CorWave, based in France, spent more than a decade on a left ventricular assist system that does not spin blood with a rotary impeller. A flexible membrane ripples, the company says, in a motion borrowed from marine animals, so the pump can keep a pulse instead of a flat flow. Rotary pumps already keep people alive for years. Bleeding, stroke and clots remain the bill.
St Vincent’s Hospital Sydney carried out the world’s first-in-human implant of that pump. Cardiothoracic surgeon Paul Jansz led the case. The patient was Michael Smith, 67, a former food-processing worker from Leeton. After weeks in intensive care he was heading home on the device, waiting for a donor heart.
The study met its primary endpoint: no device-related adverse events at 30 days. Functional status improved to NYHA class I before discharge. On post-operative day 84 the pump came out during a successful transplant. Early checks of the pump and outflow graft found no thrombus. Cardiac index rose above 2.5 L/min/m² from 1.6 before surgery. The membrane held an aortic pulse pressure of 25.5 ± 6.1 mmHg, at times above 40 mmHg, and the aortic valve kept opening even with a post-op ejection fraction of 15% to 20%.
The physiologic pulse that we observed in the first CorWave patient stands out from the results we have observed in patients assisted with continuous-flow LVAD, in use since the 2000s.
Chris Hayward, principal investigator, St Vincent’s Hospital Sydney
Louis de Lillers, CorWave’s chief executive, called the case the product of more than a decade of engineering. Jansz said the operation felt close to today’s pumps, with one difference: the pulse is preserved. Smith said he felt no tiredness after the operation, and that he felt 21 again. Hayward still wants more patients before anyone treats one case as a standard of care.
CORWAVE’S PATH OUT OF FRANCE
- October 2024: Joins the Scaling Club’s Cardiovascular Therapies group.
- May 28, 2025: Jansz implants the LVAS in Smith at St Vincent’s, Sydney.
- 30 days: Primary safety endpoint is met, with no device-related adverse events.
- Day 84: Smith receives a heart transplant and the pump is explanted without thrombus on early inspection.
- September 26, 2025: Hayward presents the first-patient data at the Heart Failure Society of America meeting in Minneapolis.
The trial is built for about 20 implants over three years across six hospitals. Four of those sites are in Europe. St Vincent’s and The Alfred in Melbourne are the only non-European partners. The first chest was still Australian. The club later said CorWave had raised more than €80 million in equity, including the EIC Fund’s first direct investment in a private company.
Last year, a team at St Vincent’s Hospital in Sydney implanted the CorWave LVAS – the first heart pump built on wave technology, a flexible membrane inspired by the way dolphins and other marine animals swim. Instead of just spinning blood continuously, it ripples, restoring a… pic.twitter.com/PLC7q6Cy5S
— EIC Scaling Club (@ScalingClubEIC) August 19, 2026
67 Percent Growth Inside a 120-Company Club
The seven firms are members of a curated EU programme that now lists 120 European deep tech scale-ups. Tech Tour runs it with Bpifrance (EuroQuity), Hello Tomorrow, Tech.eu (Webrazzi), EurA and IESE Business School, under EIC Business Acceleration Services. Members were pulled from more than 300 nominations by investors and EU member-state officials, with a stated path toward a €1 billion valuation.
The club’s published impact report is the reason Brussels can claim the roster is working on paper. It is also the reason the overseas firsts sting. Thirty-five percent of members have already expanded outside the EU. That is the leak the club was funded to slow.
WHAT THE CLUB HAS COUNTED
- Funding lift: Members posted 67 percent funding growth over 14 to 20 months, against 26 percent for 240 eligible firms that applied and were not selected.
- Capital stacked: About €2.13 billion raised since joining, and about €5.47 billion in total, with a combined valuation put at €10-13 billion.
- Headcount and deals: 2,182 new jobs and 200 strategic partnerships; 76 percent of members say they won new clients.
- The outward turn: 35 percent of members have expanded their business outside the EU.
Patrik Sobocki, an EIC board member and club council member, said the figures show the strength of Europe’s deep tech talent and the need for support if those firms are to scale globally. On September 24, 2026 the health cohort sat down with AstraZeneca and Medtronic in Gothenburg. Mentors around the club keep repeating a smaller test. Vesselin Drobenov, who leads Bulgaria’s Digital Health Innovations Cluster, told the programme the first 10 clients matter more than most metrics.
Ligence Heart Is Cleared for American Echo Labs
Ligence, in Kaunas, Lithuania, sells software that reads transthoracic echo images, finds the chambers, takes the measurements and writes the report. The company says a routine exam and write-up that takes about 30 minutes can fall to 15 minutes, so a lab can see more patients without hiring in lockstep. The product already carries a European CE mark. The commercial prize the firm announced is American.
On November 26, 2025 Ligence said Ligence Heart had its first U.S. FDA 510(k) clearance, backed by a validation study at an independent U.S. echo core lab. On April 14, 2026 it announced a second FDA 510(k) clearance for version 4.0.0, adding fully automated left ventricular global longitudinal strain and a private-cloud install. The company said that build was available immediately for U.S. providers.
Global Longitudinal Strain is an incredibly powerful metric for early disease detection, but its adoption is often bottlenecked by how time-consuming it is to measure manually. By automating view classification and contour tracking, we are removing that friction. Now, LV strain measurement is accessible for almost all patients.
Arnas Karužas, MD, PhD, co-founder and CEO of Ligence
Strain is the useful specimen here, not the press language. It is a contour-tracking measurement that can flag weak heart muscle before ejection fraction falls, and it is slow when a human traces every frame. Ligence’s bet is that U.S. labs will pay to take that tracing off the desk. European hospitals can already install the CE-marked tool. The second clearance, and the sentence about U.S. availability, show where the firm is trying to get paid first.
The $56 Million Stroke Bet Runs Through the FDA
Anaconda Biomed, in Barcelona with a U.S. office in Marin, California, makes a self-expanding funnel catheter for mechanical thrombectomy in acute ischemic stroke. The funnel is meant to swallow a clot, hold flow, and cut the chance that fragments drift into smaller brain arteries. The ANA5 Funnel Catheter already has a CE mark. In the United States the ANA Funnel Catheter is still investigational.
On September 23, 2026 the company closed $56 million led by Omega Funds, with Spain’s FOCO co-investment fund (managed by COFIDES) joining Asabys, Ysios Capital and CDTI. The cheque is not a European launch fund. It is meant to finish the 327-subject ATHENA trial, a prospective, randomized pivotal IDE study of safety and performance, and to push a wider neurovascular set (ANA5, ANA6, ANA8 and the Conda stent retriever) through global reviews.
Trent Reutiman, Anaconda’s chief executive, said the round lets the firm keep working on large-vessel occlusion, with the aim of cutting disability and death. Claudio Nessi of Omega Funds called ischemic stroke a large and growing market and said the team now has the resources to try to establish itself in interventional neurovascular devices. Anaconda’s own release puts the backdrop at seven million stroke deaths a year and nearly 270,000 mechanical thrombectomy procedures worldwide in 2026, a slice of the patients who might be treated. A CE-marked funnel can already enter European labs. The 327-person study is the U.S. door.
Check Point Care Already Runs Seven-Country Wards
Not every name on the list is still waiting on a first patient. Check Point Care, from Kazanlak in central Bulgaria, sells wearable monitors and a 24/7 virtual care centre that the firm pitches as a ward at home. The wearables stream clinical-grade ECG, blood pressure, oxygen saturation, respiratory rate and temperature. Software turns those streams into digital biomarkers and a personalised digital twin, and a clinical team calls the treating doctor when the pattern turns.
The company’s tech has supported over 95,000 acute patients and analyses over 16.5 million data points a month. An EIC Scaling Club interview with Kaja Vidic, the firm’s chief business development officer, put the live service in seven countries, with expansion talk aimed at Denmark and Iceland. The same club write-up described a wearable that can capture up to 100 vital parameters and a platform that computes 10,000 digital biomarkers. After MEDICA 2025, an EIC trade-fair note said the company had more than 10,000 pending orders.
This is the counter-case the overseas firsts do not erase. Remote monitoring does not need an operating theatre in Sydney or a 327-subject IDE. It needs hospital contracts, a night desk, and a device patients will wear. Check Point Care is already selling that loop. The harder devices on the same roster still have to prove they work in someone else’s theatre before a European payer will treat them as routine care.
Why a CE Mark Still Leaves the Invoice Unpaid
A CE mark lets a device be sold across the EU. It does not force any health system to buy it. Reimbursement is still a national job, with separate health-technology assessments, codes and prices. NAMSA, a device research group, puts the practical rule in one line: if you start reimbursement work after the CE mark, you are already late. Certification clocks of 13 to 18 months from submission are common on complex files, and they can run longer.
Brussels knows the bottleneck. On December 16, 2025 the European Commission put forward a targeted revision of the Medical Device Regulation and the in-vitro diagnostic rules, and it has been writing maximum notified-body timelines so a file cannot sit without a clock. Those repairs are still moving through Parliament and the Council. They do not, on their own, make a German or Romanian hospital pay.
Filip Peters, chief executive of Swedish sensor firm Acorai, which is not on this seven-company list, said he expects a U.S. launch in the third quarter of 2027 while Europe waits. He is chasing FDA first because U.S. studies of accuracy and usability can run in parallel, and because Medicare has a temporary coverage path for emerging technology. In Europe, he said, the work is sequential and costs at least six extra months. For drugs, the wait is longer still. EFPIA’s 2025 Patient W.A.I.T. Indicator put average time from EU approval to reimbursement at 597 days, from 158 days in Germany to 1,110 days in Romania. Arctic Therapeutics will meet that medicines clock. The device firms meet a different maze with the same shape.
WHAT STILL SITS BETWEEN A LAB AND A WARD
- The stamp: CE marking opens 27 markets and pays for none of them.
- The invoice: Each country runs its own assessment, code and price, so a Spanish or Lithuanian win does not travel.
- The trial that raises money: U.S. IDE studies and FDA 510(k) files are where large funds still underwrite risk, as Anaconda’s round shows.
- The first chest: First-in-human sites follow experienced theatres and ethics boards, which is how a French pump’s first case ran in Sydney even with four European hospitals on the protocol.
That is why a club built to keep European deep tech in Europe can still report that 35 percent of its members have taken business outside the EU. Scientific proof is not a purchase order. The first 10 clients are.
Asgard, MiMARK and Arctic Are Still Pre-Ward
The rest of the list is earlier in the same bind. The table is the scoreboard. The science under it is not yet a standard test or a standard dose.
WHERE THE SEVEN STAND
| Company | Country | Product | Status now |
|---|---|---|---|
| Check Point Care | Bulgaria | Wearable monitors and a virtual ward | Over 95,000 acute patients, 16.5 million data points a month, seven countries |
| Ligence | Lithuania | Ligence Heart echo software | CE mark plus two FDA 510(k)s; U.S. strain build announced April 14, 2026 |
| MiMARK Diagnostics | Spain | WomEC uterine-fluid test | Clinical validation; not on sale |
| Anaconda Biomed | Spain | ANA Funnel Catheter | ANA5 CE marked; 327-subject U.S. IDE funded with $56 million |
| CorWave | France | Wave-membrane LVAS | First implant in Sydney on May 28, 2025; transplant on day 84 |
| Arctic Therapeutics | Iceland | AT-001 (dementia), AT-004 (skin) | €26.5 million Series A; EMA-cleared IIb/III trial in HCCAA |
| Asgard Therapeutics | Sweden | AT-108 in-body reprogramming | €30 million Series A; clinical trial application aimed at 2027 |
MiMARK Diagnostics, a 2021 spinout from Vall d’Hebron University Hospital in Barcelona, is building WomEC, an ELISA that looks for protein biomarkers in uterine fluid so postmenopausal women with abnormal bleeding might skip some biopsies and hysteroscopies. Chief executive Marina Rigau’s team used samples from almost 1,000 patients to pick the markers. In 2025 the firm said it was aiming, in validation, for 97 percent sensitivity and 70 to 78 percent specificity, and that it would rather license the assay to large diagnostics companies than sell it in every market itself. Until that validation closes, WomEC is a panel, not a routine order.
Asgard Therapeutics, in Lund, wants to turn tumour cells into antigen-presenting dendritic cells inside the patient. Lead programme AT-108 uses a replication-deficient adenoviral vector to deliver three transcription factors. Cristiana Pires, the chief executive and a co-founder with Filipe Pereira and Fábio Rosa, has said the point is to recreate the needed immune cells in the body instead of manufacturing them outside it. The company raised a €6 million seed in 2021 and a €30 million Series A in March 2024, co-led by RV Invest and Johnson & Johnson Innovation’s JJDC, with Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden still in. Pereira’s group at Lund, with Herlev Hospital in Denmark, also won a €2.5 million EIC Transition grant. Asgard is aiming to file a clinical trial application in 2027. There is no treated patient yet.
Arctic Therapeutics, in Reykjavik, is the medicines case in a device-heavy list. It closed an oversubscribed €26.5 million Series A on January 22, 2025, with the EIC Fund among the backers, to push AT-001, an oral anti-amyloid candidate, and AT-004, a topical anti-inflammatory. The European Medicines Agency had already approved a pivotal phase IIb/III trial of AT-001 in hereditary cystatin C amyloid angiopathy, a rare familial dementia. A phase IIa trial of AT-004 in acne is planned in Europe. Ivar Hakonarson, co-founder and chief executive, has said the aim is to slow or prevent amyloid disease rather than chase symptoms. Those trials will still have to cross the 597-day class of national reimbursement waits if the drugs work.
Check Point Care is already inside wards in seven countries. Ligence can sell a CE-marked tool in Europe and is pitching strain software to U.S. labs. Anaconda’s funnel is CE-marked at home and still investigational in the United States, where the $56 million is meant to finish the evidence. CorWave’s first pulse ran through an Australian chest. Asgard is aiming at a 2027 filing. Until a European hospital pays, several of these files remain a protocol, a clearance letter and a raise.
Disclaimer: This article is news reporting and analysis of publicly described medical devices, diagnostics and drug programmes. It is for information only and is not medical advice, an investment recommendation, or a view on whether any product is safe or effective for a given patient. Readers should consult a licensed physician for clinical decisions and a qualified financial or legal adviser before acting on any company, trial or fundraising detail. Figures, trial statuses, clearances and financing terms reflect the company statements, hospital notices, club reports and regulator records cited here and can change as studies read out and reviews conclude.
-
BUSINESS5 months agoAramco Crash Kills 14 Two Days After Oil Restart
-
NEWS6 months agoSalah Captained Egypt to Their First World Cup Win
-
GAMING2 months agoZelda’s 40th Switch 2 Ships Without a Zelda Game
-
NEWS3 months agoApple Labor Day Deals Hide June’s Memory Price Hike
-
NEWS4 months agoEl Niño Puts Israel’s Needed Winter Rain on a Flood Clock
-
GAMING2 months agoPalworld 1.0.4 Adds Palpedia Search After the 1.0 Launch
-
NEWS4 months agoSaudi Visa Routes Split Nigerian Travelers Into Two Speeds
-
BUSINESS9 months agoBAE’s 60-Year Saudi Franchise Now Runs Through Taif
